Bioxytran (BIXT) Emerging Growth Virtual Conference summary

Technology platforms and clinical progress

• Developed three AI-driven platform technologies: a broad-spectrum oral antiviral, an oxygenation molecule for stroke, and a cancer/metastasis treatment.

• Oral antiviral achieved 100% viral reduction in seven days in clinical trials and is effective against COVID-19, influenza, and RSV.

• Dose optimization study underway, with plans for a registrational trial in India.

• Oxygenation molecule leverages FDA-approved device for tissue oxygenation detection.

• Cancer platform targets metastasis, with ongoing research collaborations.

Bird flu initiative and economic impact

• Broad-spectrum antiviral is being adapted for bird flu, leveraging its water-soluble formulation for mass treatment in poultry.

• Academic partnerships, notably with the University of Georgia, are central to developing bird flu therapeutics.

• $100 million in USDA funding aligns with the company's approach, favoring therapeutics and prevention over vaccination.

• Culling and vaccination are seen as economically unsustainable; therapeutics offer a scalable alternative.

• Licensing strategy targets veterinary companies for distribution, with potential for significant revenue.

Licensing, partnerships, and funding strategy

• Focused on licensing to big pharma for both human and animal health applications.

• Domestic initiatives include dermatology, oncology, and ophthalmology, with ongoing feedback from large pharma.

• International strategy gaining traction in Japan, with positive feedback from major pharma and pending NDAs.

• Government funding is being pursued, but non-dilutive sources are limited outside of antivirals.

• Collaborations under NDAs could lead to imminent agreements.